de Zeeuw, Dick2; Akizawa, Tadao2; Agarwal, Rajiv2; Audhya, Paul2; Bakris, George L2; Chin, Melanie2; Krauth, Melissa2; Lambers Heerspink, Hiddo J2; Meyer, Colin J2; McMurray, John J2; Parving, Hans-Henrik1; Pergola, Pablo E2; Remuzzi, Giuseppe2; Toto, Robert D2; Vaziri, Nosratola D2; Wanner, Christoph2; Warnock, David G2; Wittes, Janet2; Chertow, Glenn M2
1 Endocrinology, Department of, Abdominal Centre, Rigshospitalet, The Capital Region of Denmark2 unknown
the Occurrence of Renal Events (BEACON)
Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.
American Journal of Nephrology, 2013, Vol 37, Issue 3, p. 212-22